Quick Summary
- Sustained and Improving Efficacy: The ICOTYDE Icotrokinra Results from the one-year Phase 3 trials showed that skin clearance didn’t just last—it improved. In the ICONIC-ADVANCE 1 study, complete skin clearance (PASI 100) rose from 41% at Week 24 to 49% at Week 52.
- Transformative for Adolescents: Nearly 60% of adolescent patients (ages 12+) achieved completely clear skin after one year of treatment. With 86% reaching near-clear skin (PASI 90), these ICOTYDE Icotrokinra Results establish the once-daily pill as a powerful new systemic option for younger populations.
- Consistent Safety Profile: Throughout the 52-week ICONIC-LEAD and ADVANCE studies, no new safety signals were identified. The treatment maintained a favorable safety profile with infection rates remaining lower than those observed in competitors like deucravacitinib during head-to-head assessments.
ICOTYDE Icotrokinra Results from the latest Phase 3 clinical trials mark a significant shift in the treatment landscape for moderate-to-severe plaque psoriasis. Johnson & Johnson recently presented long-term 52-week data at the 2026 American Academy of Dermatology (AAD) Annual Meeting, confirming that this once-daily oral peptide provides lasting skin clearance and a favorable safety profile for both adults and adolescents.
Breakthrough ICOTYDE Icotrokinra Results in Phase 3 Trials
The one-year data, derived from the ICONIC-ADVANCE 1 and 2 studies, evaluated the efficacy of icotrokinra against both a placebo and the active comparator, deucravacitinib. The findings were notable: the percentage of patients achieving PASI 100 (completely clear skin) actually increased between Week 24 and Week 52.
In the ADVANCE 1 study, complete clearance rates rose from 41% to 49%, while ADVANCE 2 saw an increase from 33% to 48%. These ICOTYDE Icotrokinra Results demonstrate that the medication’s efficacy is not only maintained but potentially improves with long-term, consistent dosing.
Detailed Efficacy Data: A Closer Look at the Numbers
The following table summarizes the primary endpoints and the significant skin clearance achieved across the ICONIC clinical program.
| Study Group | Metric | Week 24 Result | Week 52 Result |
| ICONIC-ADVANCE 1 (Adults) | PASI 100 (Clear Skin) | 41% | 49% |
| ICONIC-ADVANCE 2 (Adults) | PASI 100 (Clear Skin) | 33% | 48% |
| ICONIC-LEAD (Adolescents) | PASI 100 (Clear Skin) | — | 57% |
| ICONIC-LEAD (Adolescents) | PASI 90 (Near Clear) | — | 86% |
| ICONIC-LEAD (Adolescents) | IGA 0 (Total Clearance) | — | 61% |
Read More: Johnson & Johnson’s Icotrokinra Shows Significant Skin Clearance in Difficult-to-Treat Psoriasis
Safety and Efficacy in Adolescents
The ICONIC-LEAD study focused on a vulnerable demographic: patients aged 12 and older. The ICOTYDE Icotrokinra Results for this group were particularly impressive. Nearly 60% of adolescents achieved completely clear skin at the one-year mark, with 92% of those who reached PASI 90 at Week 24 maintaining that response through Week 52.
BiotechReality JobFinder
- Senior Business Analyst talent is currently being sought by Johnson & Johnson for their leading MedTech enterprise operations. This exciting, […]
- Patent Coordinator professionals are currently in high demand as global healthcare organizations expand their intellectual property divisions. Our third-party job […]
- Product Sales Specialist Cell Culture Media opportunities like this do not come around often! BRJF is featuring an opening at […]
- A Manufacturing Process Technician vacancy has officially opened at Amgen’s premier manufacturing site in Dun Laoghaire, Dublin. This is a […]
- Reproductive Health Product Specialist positions offer unique career paths for biotechnology professionals who want to combine deep scientific knowledge with […]
- If you are looking to advance your pharmaceutical career in Singapore, this premier Manufacturing Biotechnologist Job at Roche offers an […]
Future Regulatory Outlook: Expanding the Reach of ICOTYDE
Following the landmark ICOTYDE Icotrokinra Results presented at the 2026 AAD Annual Meeting, the regulatory trajectory for this first-in-class oral peptide is moving into a high-growth phase. Having already secured FDA approval in March 2026 for moderate-to-severe plaque psoriasis in both adults and adolescents, Johnson & Johnson is now focused on global expansion and label extensions.
Global Market Access and Pending Approvals
The success of the ICONIC clinical program has paved the way for submissions to international health authorities. The focus is currently on the European market, where a decision from the European Medicines Agency (EMA) is anticipated later in 2026.
| Regulatory Agency | Current Status | Expected Timeline |
| U.S. FDA | Approved (March 18, 2026) | Commercial Launch Underway |
| EMA (Europe) | Under Review (Filed Sept 2025) | Decision Expected Q3/Q4 2026 |
| PMDA (Japan) | Phase 3 Trials Ongoing | Filing Anticipated 2027 |
| NMPA (China) | Clinical Development | Filing Anticipated 2027+ |
Read More: Johnson & Johnson’s Imaavy Wins European Commission Approval for Generalized Myasthenia Gravis
Pipeline Expansion: Beyond Plaque Psoriasis
The ICOTYDE Icotrokinra Results in skin clearance have validated the IL-23 receptor as a potent target for oral peptides. Consequently, J&J is aggressively pursuing label extensions for other inflammatory and immune-mediated (I&I) conditions.
- Psoriatic Arthritis (PsA): Two pivotal Phase 3 trials, ICONIC-PsA 1 and 2, are currently evaluating icotrokinra in biologic-naive and biologic-experienced patients. Positive data here could lead to a supplemental New Drug Application (sNDA) by late 2027.
- Inflammatory Bowel Disease (IBD): Following promising Phase 2b results, the ICONIC-UC (Ulcerative Colitis) and ICONIC-CD (Crohn’s Disease) Phase 3 programs are active. These represent significant market opportunities, as oral options for IBD remain a high unmet need.
- Head-to-Head Superiority: The ICONIC-ASCEND study is uniquely positioned to demonstrate the superiority of this oral pill against the injectable biologic Stelara. If successful, this could shift the regulatory “standard of care” definition for first-line systemic therapy.
Merck’s Enpatoran FDA Breakthrough Therapy Designation Granted for Cutaneous Lupus Treatment
Merck has secured an FDA Breakthrough Therapy designation for enpatoran, an investigational oral TLR7/8 inhibitor aiming to address the high unmet need in lupus patients […]
Vertex Acquires Crinetics Pharmaceuticals to Expand Rare Disease Portfolio with PALSONIFY
Vertex Acquires Crinetics Pharmaceuticals under a definitive merger agreement, where Vertex will purchase all outstanding shares of Crinetics common stock for $85.00 per share in […]
Novartis Acquires Myricx Bio to Advance Next-Generation NMTi Antibody-Drug Conjugate Pipeline
Novartis has announced a definitive agreement to acquire UK-based biotechnology firm Myricx Bio for USD 1.1 billion upfront plus USD 400 million in milestones, gaining […]
Strategic Commercial Positioning
With the expiration of patents for major biologics like Stelara, J&J is positioning ICOTYDE as the next-generation successor. Analysts suggest that the combination of “biologic-like” efficacy and the convenience of a once-daily pill could allow icotrokinra to capture a dominant share of the oral psoriasis market, currently contested by TYK2 inhibitors.
The favorable ICOTYDE Icotrokinra Results in the adolescent population (12+) provide a distinct regulatory advantage, as many competing oral systemics are currently restricted to adult use only.
